Sertraline for the treatment of depression in coronary artery disease and heart failure

Bibliography

• MUSSELMAN DL, EVANS DL, NEMEROFF CB: The relationship of depression to cardiovascular disease: epidemiology, biology, and treatment. Arch. Gen. Psychiatry (1998) 55:580-592.
   PubMed Web of Science ®Google Scholar
• RUDISCH B, NEMEROFF CB: Epidemiology of coronary artery disease and depression. Biol. Psychiatry (2003) 54:227-240.
   PubMed Web of Science ®Google Scholar
• JIANG W, KRISHNAN RR, O’CONNOR CM: Depression and heart disease: evidence of a link, and its therapeutic implications. CNS Drugs (2002) 16:111-127.
   PubMedGoogle Scholar
• RUMSFELD JS, JONES PG, WHOOLEY MA et al.: Depression predicts mortality and hospitalization in patients with myocardial infarction complicated by heart failure. Am. Heart J. (2005) 150(5):961-967.
   PubMed Web of Science ®Google Scholar
• CONNERNEY I, SHAPIRO PA, McLAUGHLIN JS et al.: Relation between depression after coronary artery bypass surgery and 12-month outcome: a prospective study. Lancet (2001) 358:1766-1771.
   PubMed Web of Science ®Google Scholar
• MALLIK S, KRUMHOLZ HM, LIN ZQ et al.: Patients with depressive symptoms have lower health status benefits after coronary artery bypass surgery. Circulation (2005) 111:271-277.
   PubMed Web of Science ®Google Scholar
• JOYNT KE, WHELLAN DJ, O’CONNOR CM: Why is depression bad for the failing heart? A review of the mechanistic relationship between depression and heart failure. J. Card. Fail. (2004) 10(3):258-270.
   PubMed Web of Science ®Google Scholar
• RUMSFELD JS, HAVRANEK EP, MASOUDI F et al.: Depressive symptoms are the strongest predictors of short-term declines in health status in patients with heart failure. J. Am. Coll. Cardiol. (2003) 42:1811-1817.
   PubMed Web of Science ®Google Scholar
• VACCARINO V, KASL S, ABRAMSON J, KRUMHOLZ HM: Depressive symptoms and risk of functional decline and death in patients with heart failure. J. Am. Coll. Cardiol. (2001) 38(1):199-205.
   PubMed Web of Science ®Google Scholar
• MURBERG TE, FURZE G: Depressive symptoms and mortality in patients with congestive heart failure: a six-year follow-up study. Med. Sci. Monit. (2004), 10(12):CR643-CR648.
   PubMedGoogle Scholar
• SULLIVAN MD, LEVY WC, CRANE BA et al.: Usefulness of depression to predict time to combined end point of transplant or death for outpatients with advanced heart failure. Am. J. Cardiol. (2004) 94:1577-1580.
   PubMed Web of Science ®Google Scholar
• RUO B, RUMSFELD JS, HLATKY MA et al.: Depressive symptoms and health-related quality of life: the Heart and Soul Study. JAMA (2003) 290:215-221.
   PubMed Web of Science ®Google Scholar
• PLANTE GE: Depression and cardiovascular disease: a reciprocal relationship. Metab. Clin. Exp. (2005) 54(Suppl. 1):45-48.
   PubMed Web of Science ®Google Scholar
• SHIMBO D, DAVIDSON KW, HAAS DC, FUSTER V, BADIMON JJ: Negative impact of depression on outcomes in patients with coronary artery disease: mechanisms, treatment considerations, and future directions. J. Thromb. Haemost. (2005) 3:897-908.
   PubMed Web of Science ®Google Scholar
• PARISSIS JT, FOUNTOULAKI K, PARASKEVAIDIS I, KREMASTINOS D: Depression in chronic heart failure: novel pathophysiological mechanisms and therapeutic approaches. Expert Opin. Investig. Drugs (2005) 14(5):567-577.
   PubMed Web of Science ®Google Scholar
• GLASSMAN AH, ROOSE SP, BIGGER JT Jr: The safety of tricyclic antidepressants in cardiac patients: risk-benefit reconsidered. JAMA (1993) 269:2673-2675.
   PubMed Web of Science ®Google Scholar
• SHELINE YI, FREEDLAND KE, CARNEY RM: How safe are serotonin reuptake inhibitors for depression in patients with coronary heart disease? Am. J. Med. (1997) 102:54-59.
   PubMedGoogle Scholar
• SONG F, FREEMANTLE N, SHELDON TA et al.: Selective serotonin reuptake inhibitors: meta-analysis of efficacy and acceptability. Br. Med. J. (1993) 306:683-687.
   PubMed Web of Science ®Google Scholar
• CARRASCO JL, SANDNER C: Clinical effects of pharmacological variations in selective serotonin reuptake inhibitors: an overview. Int. J. Clin. Pract. (2005) 59(12):1428-1434.
   PubMed Web of Science ®Google Scholar
• MAURER- SPUREJ E: Serotonin reuptake inhibitors and cardiovascular disease: a platelet connection. Cell. Mol. Life Sci. (2005) 6:159-170.
   Google Scholar
• PFIZER, INC.: Zoloft™ (Sertraline) Package Insert. Pfizer, Inc., USA (2002).
   Google Scholar
• HIEMKE C, HARTTER S: Pharmakocinetics of selective serotonin reuptake inhibitors. Pharmacol. Ther. (2000) 85:11-28.
   PubMed Web of Science ®Google Scholar
• RICHELSON E: Pharmacology of antidepressants – characteristics of the ideal drug. Mayo Clin. Proc. (1994) 69:1069-1081.
   PubMed Web of Science ®Google Scholar
• OWENS M J, MORGAN WN, PLOTT SJ, NEMEROFF CB: Neurotransmitter receptor and transporter binding profile of antidepressants and their metabolites. J. Pharmacol. Exp. Ther. (1997) 283:1305-1322.
   PubMed Web of Science ®Google Scholar
• VAN HARTEN J: Clinical pharmacokinetics of selective serotonin reuptake inhibitors. Clin. Pharmacokinet. (1993) 24:203-220.
   PubMed Web of Science ®Google Scholar
• LEVINE B, JENKINS AJ, SMIALEK JE: Distribution of sertraline in postmortem cases. J. Anal. Toxicol. (1994) 18:272-274.
   PubMed Web of Science ®Google Scholar
• RONFELD RA, TREMAINE LM, WILNER KD: Pharmacokinetics of sertraline and its N-demethyl metabolite in elderly and young male and female volunteers. Clin. Pharmacokinet. (1997) 32(suppl. 1):22-30.
   PubMed Web of Science ®Google Scholar
• RUDORFER MV, POTTER WZ: The role of metabolites of antidepressants in the treatment of depression. CNS Drugs (1997) 7:273-312.
   PubMed Web of Science ®Google Scholar
• DEVANE CL: Metabolism and pharmacokinetics of selective serotonin reuptake inhibitors. Cell. Mol. Neurobiol. (1999) 19(4):443-466.
   PubMedGoogle Scholar
• PRESKORN SH, LANE RM : Sertraline 50 mg daily: the optimal dose in the treatment of depression. Int J. Clin. Psychopharmacol. (1995) 10:129-141.
   PubMed Web of Science ®Google Scholar
• STOCK AJ, KOFOED L: Therapeutic interchange of fluoxetine and sertraline: experience in the clinical setting. Am. J. Hosp. Pharm. (1994) 51:2279-2281.
   PubMedGoogle Scholar
• LANE RM: Pharmacokinetic drug interaction potential of selective serotonin reuptake inhibitors. Int. Clin. Psychopharmacol. (1996) 11(Suppl. 5):31-61.
   PubMed Web of Science ®Google Scholar
• SCHWARTZ AC, ROTHBAUM BO: Review of sertraline in post-traumatic stress disorder. Expert Opin. Pharmacother. (2002) 3(10):1489-1499.
   PubMedGoogle Scholar
• OZDEMIR V, NARANJO CA, HERRMANN N et al.: The extent and determinants of changes in CYP2D6 and CYP1A2 activities with therapeutic doses of sertraline. J. Clin. Psychopharmacol. (1998) 18(1):55-61.
   PubMedGoogle Scholar
• SPROULE BA, OTTON SV, CHEUNG SW et al.: CYP2D6 inhibition in patients treated with sertraline. J. Clin. Psychopharmacol. (1997) 17(2):102-106.
   PubMed Web of Science ®Google Scholar
• ALDERMAN J, PRESKORN SH, GREENBLATT DJ et al.: Desipramine pharmacokinetics when coadministered with paroxetine or sertraline in extensive metabolizers. J. Clin. Psychopharmacol. (1997) 17(4):284-291.
   PubMed Web of Science ®Google Scholar
• KURTZ DL, BERGSTROM RF, GOLDBERG MJ, CERIMELE BJ: The effect of sertraline on the pharmacokinetics of desipramine and imipramine. Clin. Pharmacol. Ther. (1997) 62(2):145-156.
   PubMed Web of Science ®Google Scholar
• ZUSSMAN BD, DAVIS CC, FOWLES SE et al.: Sertraline, like other SSRIs, is a significant inhibitor of desipramine metabolism in vivo. Br. J. Clin. Pharmacol. (1995) 39:550P-551P.
   Google Scholar
• SOLAI LK, MULSANT BH, POLLOCK BG et al.: Effect of sertraline on plasma nortriptyline levels in depressed elderly. J. Clin. Psychiatry (1997) 58(10):440-443.
   PubMed Web of Science ®Google Scholar
• PRESKORN SH, ALDERMAN J, CHUNG M et al.: Pharmacokinetics of desipramine coadministered with sertraline or fluoxetine. J. Clin. Psychopharmacol. (1994) 14(2):90-98.
   PubMed Web of Science ®Google Scholar
• MCRAE AL, BRADY KT: Review of sertraline and its clinical applications in psychiatric disorders. Expert Opin. Pharmacother. (2001) 2(5):883-892.
   PubMedGoogle Scholar
• RAPEPORT WG, WILLIAMS SA, MUIRHEAD DC et al.: Absence of a sertraline-mediated effect on the pharmacokinetics and pharmacodynamics of carbamazepine. J. Clin. Psychiatry (1996) 57(Suppl. 1):20-23.
   PubMed Web of Science ®Google Scholar
• PINNINTI NR, DE LEON J: Interaction of sertraline with clozapine. J. Clin. Psychopharmacol. (1997) 17(2):119-120.
   PubMed Web of Science ®Google Scholar
• CENTORRINO F, BALDESSARINI RJ, FRANKENBURG FR et al.: Serum levels of clozapine and norclozapine in patients treated with selective serotonin reuptake inhibitors. Am. J. Psychiatry (1996) 153(6):820-822.
   PubMed Web of Science ®Google Scholar
• HOEHNS JD, FOUTS MM, KELLY MW, TU KB: Sudden cardiac death with clozapine and sertraline combination. Ann. Pharmacother. (2001) 35(7-8):862-866.
   PubMed Web of Science ®Google Scholar
• GOODNICK PJ, GOLDSTEIN BJ: Selective serotonin reuptake inhibitors in affective disorders-I. Basic pharmacology. J. Psychopharmacol. (1998) 12(3):S5-S20.
   Google Scholar
• KAUFMAN KR, GERNER R: Lamotrigine toxicity secondary to sertraline. Seizure (1998) 7(2):163-165.
   PubMed Web of Science ®Google Scholar
• TAMAM L, OZPOYRAZ N: Selective serotonin reuptake inhibitor discontinuation syndrome: a review. Adv. Ther. (2002) 19(1):17-26.
   PubMed Web of Science ®Google Scholar
• FAVA M, ROSENBAUM JF, HOOG S et al.: A comparison of symptoms following treatment interruption: evidence from a randomized double-blind trial with fluoxetine, sertraline, and paroxetine. Biol. Psychiatry (1998) 43(Suppl. 8):69S.
   PubMedGoogle Scholar
• MICHELSON D, FAVA M, AMSTERDAM J et al.: Interruption of selective serotonin reuptake inhibitor treatment. Double-blind, placebo controlled trial. Br. J. Psychiatry (2000) 176:363-368.
   PubMed Web of Science ®Google Scholar
• STAHL MM, LINDQUIST M, PETTERSSON M et al.: Withdrawal reactions with selective serotonin re-uptake inhibitors as reported to the WHO system. Eur. J. Clin. Pharmacol. (1997) 53(3-4):163-169.
   PubMed Web of Science ®Google Scholar
• MAES M, VAN DER PLANKEN M, VAN GASTEL A et al.: Blood coagulation and platelet aggegation in major depression. J. Affect. Disord. (1996) 40:35-40.
   PubMed Web of Science ®Google Scholar
• VIKENES K, FARSTAD M, NORDREHAUG JE: Serotonin is associated with coronary artery disease and cardiac events. Circulation (1999) 100:483-489.
   PubMed Web of Science ®Google Scholar
• SHIMBO D, CHILD J, DAVIDSON K et al.: Exaggerated serotonin-mediated platelet reactivity as a possible link in depression and acute coronary syndromes. Am. J. Cardiol. (2002) 89:331-333.
   PubMed Web of Science ®Google Scholar
• HELMESTE D, TANG S, REIST C et al.: Serotonin uptake inhibitors modulate intracellular calcium mobilization in platelets. Eur. J. Pharmacol. (1995) 288:373-377.
   PubMed Web of Science ®Google Scholar
• CELADA P, DOLERA M, ALVAREZ E et al.: Effects of acute and chronic treatment with fluvoxamine on extracellular and platelet serotonin in the blood of major depressive patients: relationship to clinical improvement. J. Affect. Disord. (1992) 25:243-249.
   PubMed Web of Science ®Google Scholar
• SEREBRUANY VL, GLASSMAN AH, MALININ AI et al.: Sertraline Antidepressant Heart Attack Randomized Trial Study Group. Platelet/endothelial biomarkers in depressed patients treated with the selective serotonin reuptake inhibitor sertraline after acute coronary events: the Sertraline Antidepressant Heart Attack Randomized Trial (SADHART) platelet substudy. Circulation (2003) 108:939-944.
   PubMed Web of Science ®Google Scholar
• SEREBRUANY VL, SUCKOW RF, COOPER TB et al.: Relationship between release of platelet/endothelial biomarkers and plasma levels of sertraline and N-desmethylsertraline in acute coronary syndrome patients receiving SSRI treatment for depression. Am. J. Psychiatry (2005) 162:1165-1170.
   PubMedGoogle Scholar
• SHAPIRO PA, LESPERANCE F, FRASURE-SMITH N et al.: An open-label preliminary trial of sertraline for treatment of major depression after acute myocardial infarction (the SADHART trial): Sertraline Anti-Depressant Heart Attack Trial. Am. Heart J. (1999) 137:1100-1106.
   PubMed Web of Science ®Google Scholar
• GLASSMAN AH, O’CONNOR CM, CALIFF RM et al.. Sertraline treatment of major depression in patients with acute MI or unstable angina. JAMA (2002) 288:701-709.
   PubMed Web of Science ®Google Scholar
• SWENSON JR, O’CONNOR CM, BARTON D et al. AND SERTRALINE ANTIDEPRESSANT HEART ATTACK RANDOMIZED TRIAL (SADHART) GROUP: Influence of depression and effect of treatment with sertraline on quality of life after hospitalization for acute coronary syndrome. Am. J. Cardiol. (2003) 92(11):1271-1276.
   PubMed Web of Science ®Google Scholar
• SAUER WH, BERLIN JA, KIMMEL SE: Selective serotonin reuptake inhibitors and myocardial infarction. Circulation (2001) 104(16):1894-1898.
   PubMed Web of Science ®Google Scholar
• BERKMAN LF, BLUMENTHAL J, BURG M et al.: Effects of treating depression and low perceived social support on clinical events after myocardial infarction: the Enhancing Recovery in Coronary Heart Disease Patients (ENRICHD) randomized trial. JAMA (2003) 289:3106-3116.
   PubMed Web of Science ®Google Scholar
• McFARLANE A, KAMATH MV, FALLEN EL et al.: Effect of sertraline on the recovery rate of cardiac autonomic function in depressed patients after acute myocardial infarction. Am. Heart J. (2001) 142:617-623.
   PubMed Web of Science ®Google Scholar
• SEREBRUANY VL, GLASSMAN AH, MALININ AI et al.: Selective serotonin reuptake inhibitors yield additional antiplatelet protection in patients with congestive heart failure treated with antecedent aspirin. Eur. J. Heart Fail. (2003) 5:517-521.
   PubMed Web of Science ®Google Scholar
• MANN DL: Mechanisms and models in heart failure: a combinatorial approach. Circulation (1999) 100:999-1008.
   PubMed Web of Science ®Google Scholar
• MANN DL, YOUNG JB: Basic mechanisms in congestive heat failure: recognizing the role of pro-inflammatory cytokines. Chest (1994) 105:897-904.
   PubMed Web of Science ®Google Scholar
• ANKER SD, VON HAEHLING S: Inflammatory mediators in chronic heart failure: an overview. Heart (2004) 90:464-470.
   PubMed Web of Science ®Google Scholar
• ADAMOPOULOS S, PARISSIS J, KREMASTINOS D: A glossary of circulating cytokines in chronic heart failure. Eur. J. Heart Fail., (2001) 3:517-526.
   PubMedGoogle Scholar
• MAES M: Major depression and activation of the inflammatory response system. Adv. Exp. Med. Biol. (1999) 461:25-46.
   PubMed Web of Science ®Google Scholar
• PASIC J, LEVY WC, SULLIVAN MD: Cytokines in depression and heart failure. Psychosom. Med. (2003) 65:181-193.
   PubMed Web of Science ®Google Scholar
• WATKINS LR, MAIER SF, GOEHLER LE: Cytokine-to-brain communication: a review and analysis of alternative mechanisms. Life Sci. (1995) 57:1011-1026.
   PubMed Web of Science ®Google Scholar
• REICHENBERG A, YIRMIYA R, SCHOULD A et al.: Cytokine-associated emotional and cognitive disturbances in humans. Arch. Gen. Psychiatry (2001) 58:445-452.
   PubMed Web of Science ®Google Scholar
• PARISSIS J, ADAMOPOULOS S, RIGAS A et al.: Comparison of circulating proinflammatory cytokines and soluble apoptosis mediators in patients with chronic heart failure with versus without symptoms of depression. Am. J. Cardiol. (2004) 94:1326-1328.
   PubMed Web of Science ®Google Scholar
• MAES M, SONG C, LI A et al.: Negative immunoregulatory effects of antidepressants: inhibition of IFN-γ and stimulation of interleukin-10 secretion. Neuropsychopharmacology (1999) 20:370-379.
   PubMed Web of Science ®Google Scholar
• MOHR D, GOODKIN D, ISLAR J, HAUSER S, GENAIN C: Treatment of depression is associated with suppression of nonspecific and antigen-specific T(H)1 responses in multiple sclerosis. Arch. Neurol. (2001) 58:1081-1086.
   PubMed Web of Science ®Google Scholar
• STEIN PK, CARNEY RM, FREEDLAND KE et al.: Severe depression is associated with markedly reduced heart rate variability in patients with stable coronary heart disease. J. Psychosom. Res. (2000) 48:493-500.
   PubMed Web of Science ®Google Scholar
• CARNEY RM, BLUMENTHAL JA, STEIN PK et al.: Depression, heart rate variability, and acute myocardial infarction. Circulation (2001) 104:2024-2028
   PubMed Web of Science ®Google Scholar
• GRIPPO AJ, SANTOS CM, JOHNSON RF et al.: Increased susceptibility to ventricular arrhythmias in a rodent model of experimental depression. Am. J. Physiol. Heart Circ. Physiol . (2004) 286:H619-H626.
   PubMed Web of Science ®Google Scholar
• PEET M, MURPHY B, SHAY J, HORROBIN D: Depletion of omega-3 fatty acid levels in red blood cell membranes of depressive patients. Biol. Psychiatry (1998) 43:315-319.
   PubMed Web of Science ®Google Scholar
• ALBERT CM, CAMPOS H, STAMPFER MJ et al.: Blood levels of long-chain n-3 fatty acids and the risk of sudden death. N. Engl. J. Med.(2002) 346:1113-1118.
   PubMed Web of Science ®Google Scholar
• DUNBAR S, KIMBLE L, JENKINS L et al.: Association of mood disturbance and arrhythmia events in patients after cardioverter defibrillator implantation. Depress. Anxiety (1999) 9:163-168.
   PubMedGoogle Scholar
• NAHSHONI E, AIZENBERG D, STASBERG B et al.: QT dispersion in the surface electrocardiogram in ederly patients with major depression. J. Affect. Disord. (2000) 60:197-200.
   PubMed Web of Science ®Google Scholar
• SHORES M, PASCUALLY M, LEWIS N, FLATNESS D, VEITH R: Short-term sertraline treatment suppresses sympathetic nervous system activity in healthy human subjects. Psychoneuroendocrinology (2001) 26:433-439.
   PubMed Web of Science ®Google Scholar
• MAINA G, ALBERT U, SALVI V, BOGETTO F: Weight gain during long- term treatment of obsessive – compulsive disorder: a prospective comparison between serotonin reuptake inhibitors. J. Clin. Psychiatry (2004) 65(10):1365-1371.
   PubMed Web of Science ®Google Scholar
• JACOB S, SPINLER SA: Hyponatremia associated with selective serotonin – reuptake inhibitors in older adults. Ann. Pharmacother. (2006) 40(9):1618-1622.
   PubMed Web of Science ®Google Scholar